Markets:

Overview

News

Currencies

International

Treasuries

Zymeworks Inc. - Common Stock (NQ:ZYME)

14.29 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Zymeworks Inc. - Common Stock

Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge

May 30, 2025

Zymeworks is entitled to receive a $20 million milestone payment in connection with the NMPA approval of zanidatamab as part of its agreement with BeOne Medicines.

Via Stocktwits

TD Cowen Initiates Zymeworks With ‘Buy’, Cites Ziihera’s ‘Blockbuster Potential’ In Biliary Tract Cancer Therapy

May 21, 2025

The research firm expects key clinical data in late 2025 and sees Ziihera royalties funding pipeline development.

Via Stocktwits

Earnings Scheduled For May 8, 2025

May 08, 2025

Via Benzinga

Deep Dive Into Zymeworks Stock: Analyst Perspectives (4 Ratings)

March 10, 2025

Via Benzinga

Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251

March 06, 2025

Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone adds $14M to cash reserves.

Via Benzinga

Topics Earnings

12 Health Care Stocks Moving In Thursday's Pre-Market Session

January 23, 2025

Via Benzinga

Deep Dive Into Zymeworks Stock: Analyst Perspectives (10 Ratings)

December 19, 2024

Via Benzinga

In-Depth Examination Of 9 Analyst Recommendations For Zymeworks

November 22, 2024

Via Benzinga

Earnings Scheduled For March 5, 2025

March 05, 2025

Via Benzinga

Zymeworks in Focus for Insider Activity: Catalysts Ahead

January 10, 2025

Zymeworks' insider EcoR1 Capital is buying shares ahead of expected catalysts in 2025 that could drive the stock price to multiyear highs.

Via MarketBeat

What Analysts Are Saying About Zymeworks Stock

October 22, 2024

Via Benzinga

Navigating 6 Analyst Ratings For Zymeworks

June 06, 2024

Via Benzinga

FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework

November 21, 2024

Jazz Pharmaceuticals' Ziihera receives FDA accelerated approval for HER2-positive BTC. Phase 3 trial ongoing; Zymeworks secures $25 million milestone.

Via Benzinga

Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday

November 07, 2024

Via Benzinga

Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare

June 15, 2024

Shionogi, an Osaka innovative pharma, has signed an option agreement with Cilcare of France to in-license two drug candidates aimed at hearing loss in a deal worth up to $445 million. Meanwhile, XtalPi...

Via Talk Markets

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.